Home Use of an Artificial Beta Cell in Type 1 Diabetes
| العنوان: | Home Use of an Artificial Beta Cell in Type 1 Diabetes |
|---|---|
| المؤلفون: | Jennifer Pichierri, Mark L. Evans, Julia K. Mader, Craig Kollman, Martin Tauschmann, Peiyao Cheng, Katharine D. Barnard, Carsten Benesch, Sibylle Dellweg, Carlo L. Acerini, Malgorzata E Wilinska, Roman Hovorka, Manuel Holzer, Thomas R. Pieber, Jane Exall, James Yong, Sara Hartnell, Lutz Heinemann, Janet M Allen, Hood Thabit, David B. Dunger, Peter C. Hindmarsh, Lalantha Leelarathna, Harald Kojzar, Fiona Campbell, Sabine Arnolds |
| المساهمون: | Tauschmann, Martin [0000-0002-2305-2490], Wilinska, Gosia [0000-0003-2739-1753], Acerini, Carlo [0000-0003-2121-5871], Evans, Mark [0000-0001-8122-8987], Dunger, David [0000-0002-2566-9304], Hovorka, Roman [0000-0003-2901-461X], Apollo - University of Cambridge Repository |
| المصدر: | New England Journal of Medicine. 373:2129-2140 |
| بيانات النشر: | Massachusetts Medical Society, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Hypoglycemia, Article, law.invention, Insulin Infusion Systems, Randomized controlled trial, law, Diabetes mellitus, medicine, Clinical endpoint, Humans, Hypoglycemic Agents, Insulin, Child, Glycated Hemoglobin, Type 1 diabetes, Cross-Over Studies, business.industry, Equipment Design, Infusion Pumps, Implantable, General Medicine, Middle Aged, medicine.disease, Crossover study, Confidence interval, Surgery, Diabetes Mellitus, Type 1, Female, business, Algorithms |
| الوصف: | BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P |
| وصف الملف: | application/pdf |
| تدمد: | 1533-4406 0028-4793 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0feb05d04d110cf91bf418132243791Test https://doi.org/10.1056/nejmoa1509351Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c0feb05d04d110cf91bf418132243791 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|